The French start-up company Corteria Pharmaceuticals has raised €65 million in an oversubscibed Series A financing to progress its candidate therapies for heart failure. Announced on 7 September, the financing was co-led by Jeito Capital and Orbimed with participation from the existing investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital.
